CLRB

Cellectar Biosciences, Inc. NASDAQ Listed Nov 10, 2005

Healthcare ·Biotechnology ·US · cellectar.com

$3.30

Mkt Cap $10.5M

52w Low $2.43 4.8% of range 52w High $20.70

50d MA $2.92 200d MA $3.76

P/E (TTM) -0.3x

EV/EBITDA 0.2x

P/B 0.7x

Debt/Equity 0.0x

ROE -255.3%

P/FCF -0.3x

RSI (14) —

ATR (14) —

Beta 0.40

50d MA $2.92

200d MA $3.76

Avg Volume 35.4K

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

SIC Code

2834

CIK (SEC)

1279704

Phone

608 441 8120

100 Campus Drive · Florham Park, NJ 07932 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 4, 2026	BMO	-1.19	-0.53	+55.5%	2.90	+0.7%	-4.5%	-0.4%	-0.4%	+10.9%	-3.0%	—
Nov 13, 2025	BMO	-1.91	-1.41	+26.2%	2.87	-1.0%	+1.0%	+0.7%	+5.1%	-6.8%	-1.4%	—
Aug 14, 2025	BMO	-3.60	-3.39	+5.8%	4.42	-0.5%	-1.8%	+8.3%	-4.3%	-2.0%	+1.8%	—
May 13, 2025	BMO	-5.11	-3.90	+23.7%	7.20	+1.7%	+0.3%	+5.4%	-3.4%	+4.4%	+3.3%	—
Mar 13, 2025	BMO	-0.38	-0.01	+97.4%	8.99	-0.6%	+5.3%	+6.7%	+12.0%	+2.3%	-1.5%	—
Oct 29, 2024	BMO	-0.37	-0.51	-37.8%	61.50	-0.5%	+0.0%	-0.5%	-0.5%	+0.0%	+0.0%	—
Aug 13, 2024	BMO	-0.23	-0.73	-217.4%	60.60	+0.5%	-1.0%	+1.5%	+0.0%	+1.0%	+1.5%	—
May 14, 2024	BMO	-0.50	-0.40	+20.0%	95.40	+2.2%	+5.7%	-0.9%	-0.9%	-4.2%	+2.8%	—
Mar 27, 2024	BMO	-0.59	-0.66	-11.9%	109.20	+5.2%	+9.3%	-1.5%	+1.8%	-0.3%	-6.5%	—
Nov 13, 2023	BMO	-0.44	-0.82	-86.4%	62.10	+1.0%	-2.4%	-2.0%	+1.0%	+4.0%	+3.8%	—
Aug 14, 2023	BMO	-0.69	-0.73	-5.8%	48.90	-1.8%	+4.9%	-4.1%	-2.4%	+0.6%	+2.5%	—
May 4, 2023	BMO	-0.75	-0.76	-1.3%	44.40	-1.4%	-1.4%	-0.7%	-2.1%	-1.4%	+0.7%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 10	Maxim Group	Upgrade	Hold → Buy	—	$2.75	$2.84	+3.3%	+10.9%	-3.0%	+9.1%	-0.9%	+2.2%
May 14	Maxim Group	Downgrade	Buy → Hold	—	$7.20	$7.32	+1.7%	+0.3%	+5.4%	-3.4%	+4.4%	+3.3%
Dec 11	Oppenheimer	Downgrade	Outperform → Perform	—	$38.40	$12.87	-66.5%	-76.1%	-13.5%	-1.5%	-0.9%	+1.8%
Nov 19	Oppenheimer	Maintains	Outperform → Outperform	—	$53.10	$52.50	-1.1%	-9.0%	-3.1%	+1.3%	+0.0%	-0.6%
Mar 28	Roth MKM	Maintains	Buy → Buy	—	$109.20	$114.90	+5.2%	+9.3%	-1.5%	+1.8%	-0.3%	-6.5%
Mar 28	Oppenheimer	Maintains	Outperform → Outperform	—	$109.20	$114.90	+5.2%	+9.3%	-1.5%	+1.8%	-0.3%	-6.5%
Mar 4	Roth MKM	Maintains	Buy → Buy	—	$126.00	$132.00	+4.8%	+1.0%	-4.5%	-1.2%	+1.8%	-1.7%
Nov 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$57.00	$59.40	+4.2%	-0.5%	-1.6%	+3.8%	-2.1%	+0.0%
Nov 25	Brookline Capital	Maintains	Buy → Buy	—	$372.00	$372.00	+0.0%	-2.4%	+1.7%	+2.4%	+20.6%	+28.3%
Nov 25	Roth Capital	Maintains	Buy → Buy	—	$372.00	$372.00	+0.0%	-2.4%	+1.7%	+2.4%	+20.6%	+28.3%
Nov 25	Oppenheimer	Maintains	Outperform → Outperform	—	$372.00	$372.00	+0.0%	-2.4%	+1.7%	+2.4%	+20.6%	+28.3%
Nov 25	Maxim Group	Maintains	Buy → Buy	—	$372.00	$372.00	+0.0%	-2.4%	+1.7%	+2.4%	+20.6%	+28.3%
Jul 1	Oppenheimer	Maintains	Outperform → Outperform	—	$384.00	$417.00	+8.6%	+4.7%	+5.2%	+5.7%	-1.3%	+4.1%
Jun 23	Maxim Group	Maintains	Buy → Buy	—	$366.00	$387.00	+5.7%	+5.7%	-0.8%	+2.3%	-1.5%	+0.8%
Sep 13	Roth Capital	Maintains	Buy → Buy	—	$687.00	$750.00	+9.2%	+3.1%	+3.8%	-1.6%	+2.1%	-1.2%
Jul 30	Brookline Capital	Maintains	Buy → Buy	—	$642.00	$660.00	+2.8%	+1.4%	+0.9%	-0.9%	-0.9%	-2.3%
May 2	H.C. Wainwright	Maintains	Buy → Buy	—	$666.00	$678.00	+1.8%	-2.7%	+12.0%	-0.4%	-4.1%	-2.6%
Dec 21	Ladenburg Thalmann	Maintains	Buy → Buy	—	$3720.00	$3810.00	+2.4%	-2.4%	+0.0%	+9.9%	-3.0%	+0.0%

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
May 7, 2026	Longcor JarrodOff	Chief Operating Officer	Buy	8,680	$2.88	$25K	20,451	-2.94%	—
May 7, 2026	CARUSO JAMES VDir/Off	Chief Executive Officer	Buy	8,680	$2.88	$25K	20,318	-2.94%	—

Data updated apr 25, 2026 1:46am · Source: massive.com